Dainippon Sumitomo Surges on Partner Trial for Liver Drug
This article is for subscribers only.
Dainippon Sumitomo Pharma Co. surged to the highest in more than a decade yesterday after a U.S. partner’s trial of a liver disease drug worked well enough for the testing to be stopped.
Osaka-based Dainippon’s shares surged 17 percent to close at 1,906 yen in Tokyo trading, the highest level since March